Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells

被引:20
|
作者
Lu, L. [1 ,2 ]
Saunders, V. A. [1 ]
Leclercq, T. M. [1 ,2 ]
Hughes, T. P. [1 ,2 ,3 ]
White, D. L. [1 ,2 ,4 ]
机构
[1] South Australian Hlth & Med Res Inst SAHMRI, Canc Theme, Adelaide, SA, Australia
[2] Univ Adelaide, Sch Med, Discipline Med, Adelaide, SA, Australia
[3] SA Pathol, Dept Haematol, Adelaide, SA, Australia
[4] Univ Adelaide, Sch Med, Discipline Paediat, Adelaide, SA, Australia
关键词
IN-VITRO SENSITIVITY; IMATINIB MESYLATE; LEUKEMIA-CELLS; P-GLYCOPROTEIN; RESISTANCE; INHIBITOR; EFFLUX; ABL;
D O I
10.1038/leu.2015.35
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:1792 / 1794
页数:3
相关论文
共 50 条
  • [21] Superior Pyrimidine Derivatives as Selective ABCG2 Inhibitors and Broad-Spectrum ABCB1, ABCC1, and ABCG2 Antagonists
    Silbermann, Katja
    Li, Jiyang
    Namasivayam, Vigneshwaran
    Baltes, Fabian
    Bendas, Gerd
    Stefan, Sven Marcel
    Wiese, Michael
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (18) : 10412 - 10432
  • [22] Inhibition of ABCB1 and ABCG2 at the Mouse Blood Brain-Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [11C]erlotinib
    Traxl, Alexander
    Mairinger, Severin
    Filip, Thomas
    Sauberer, Michael
    Stanek, Johann
    Poschner, Stefan
    Jaeger, Walter
    Zoufal, Viktoria
    Novarino, Gaia
    Tournier, Nicolas
    Bauer, Martin
    Wanek, Thomas
    Langer, Oliver
    MOLECULAR PHARMACEUTICS, 2019, 16 (03) : 1282 - 1293
  • [23] ATP Dependent Efflux Transporters ABCB1 and ABCG2 Are Unlikely to Impact the Efficacy, or Mediate Resistance to the Tyrosine Kinase Inhibitor, Ponatinib
    White, Deborah L.
    Lu, Liu
    Clackson, Timothy P.
    Saunders, Verity A.
    Hughes, Timothy P.
    BLOOD, 2011, 118 (21) : 1180 - 1180
  • [24] Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells
    Zhang, Yongchao
    Wu, Zhuo-Xun
    Yang, Yuqi
    Wang, Jing-Quan
    Li, Jun
    Sun, Zoey
    Teng, Qiu-Xu
    Ashby, Charles R., Jr.
    Yang, Dong-Hua
    CANCERS, 2020, 12 (11) : 1 - 24
  • [25] Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo
    Lin, Fan
    Hoogendijk, Lisette
    Buil, Levi
    Beijnen, Jos H.
    van Tellingen, Olaf
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (08) : 2059 - 2064
  • [26] IMPACT OF ABCB1 AND ABCG2 POLYMORPHISMS ON RESPONSE TO IMATINIB AND 2G-TKIS THERAPY IN PATIENTS WITH CHRONIC PHASE CML
    Tiribelli, M.
    Di Giusto, S.
    Toffoletti, E.
    Penna, D.
    Griguolo, D.
    Maccari, G.
    De Marchi, F.
    Medeot, M.
    Fanin, R.
    Damiani, D.
    HAEMATOLOGICA, 2017, 102 : 438 - 439
  • [27] OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation
    Wang, Yaogeng
    Sparidans, Rolf W.
    Li, Wenlong
    Lebre, Maria C.
    Beijnen, Jos H.
    Schinkel, Alfred H.
    BRITISH JOURNAL OF PHARMACOLOGY, 2020, 177 (13) : 3060 - 3074
  • [28] Effects of the ABCG2 and ABCB1 drug transporter polymorphisms on the pharmacokinetics of bicalutamide in humans
    Kim, Kyoung-Ah
    Cha, Yu-Jung
    Lee, Hae-Mi
    Joo, Hyun-Jin
    Park, Ji-Young
    CLINICA CHIMICA ACTA, 2015, 438 : 7 - 11
  • [29] Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2
    de Gooijer, Mark C.
    de Vries, Nienke A.
    Buckle, Tessa
    Buil, Levi C. M.
    Beijnen, Jos H.
    Boogerd, Willem
    van Tellingen, Olaf
    NEOPLASIA, 2018, 20 (07): : 710 - 720
  • [30] Measurement of hepatic abcb1 and abcg2 transport activity with positron emission tomography
    Lozano, I. Hernandez
    Wulkersdorfer, B.
    Traxl, A.
    Bauer, M.
    Philippe, C.
    Stieger, B.
    Ozvegy-Laczka, C.
    Szakacs, G.
    Wanek, T.
    Hacker, M.
    Zeitlinger, M.
    Langer, O.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 : S41 - S41